

---

## MDV-3100

产品编号: D51070

CAS: 915087-33-1

分子式: C<sub>21</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S

纯度: ≥98%

InChi: InChI=1S/C<sub>21</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H<sub>3</sub>, (H,27,30)

InChi Key: WXCXUHSOUPDCQV-UHFFFAOYSA-N

Smiles: CC1(C)C(=O)N(C(=S)N1C1=CC(F)=C(C=C1)C(=O)NC)C1C=CC(C#N)=C(C=1)C(F)(F)F

外观: 固体粉末

作用通路: Androgen Receptor

溶解性: Soluble in DMSO, not in water

保存条件: Store in dry, dark place for one year.

产品介绍: Enzalutamide, also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer.